Depression & Anxiety Screening Scores
Buy and sell depression & anxiety screening scores data. PHQ-9, GAD-7, longitudinal tracking — screening score trends train mood prediction AI.
No listings currently in the marketplace for Depression & Anxiety Screening Scores.
Find Me This Data →Overview
What Is Depression & Anxiety Screening Scores Data?
Depression and anxiety screening scores represent standardized mental health assessment data collected through validated instruments like PHQ-9, GAD-7, and DASS-42 questionnaires. These scores quantify symptom severity across depression, anxiety, and related conditions using structured, reproducible measurement scales. The data is increasingly used to train artificial intelligence models for mood prediction, treatment selection, and early intervention in mental health care delivery. As a key component of the broader AI-powered mental health solutions market, screening score datasets enable developers to build predictive algorithms that support clinical decision-making, patient monitoring, and outcomes tracking at scale across primary care, workplace wellness programs, and virtual-first mental health platforms.
Market Data
$2.42 Billion
AI Mental Health Market Size (2026)
Source: Mordor Intelligence
$9.96 Billion
Projected Market Size (2031)
Source: Mordor Intelligence
26.3%
Depression Segment Market Share (2026)
Source: Fortune Business Insights
29.78%
Depression & Anxiety App Segment Share (2024)
Source: Grand View Research
3.1% (6.8 million people)
GAD Prevalence in U.S. Adults
Source: Grand View Research
Who Uses This Data
What AI models do with it.do with it.
AI-Powered Treatment Selection
Machine learning models trained on clinical depression screening datasets to develop differential treatment selection algorithms, enabling personalized medication and therapy recommendations based on patient symptom profiles.
Workplace Mental Health Programs
Employers deploying screening score data through AI platforms to monitor employee mental health, identify individuals needing intervention, and track outcomes across depression and anxiety management initiatives.
Clinical Assessment & Progress Tracking
Healthcare providers using standardized screening scores to structure assessments, support care navigation and triage, document clinical outcomes, and enable remote monitoring and relapse prediction.
Telehealth & Digital Therapeutics
Virtual-first mental health platforms leveraging screening score datasets to improve engagement, enable automated care pathways, and deliver evidence-based digital therapeutics for depression and anxiety management.
What Can You Earn?
What it's worth.worth.
Individual Screening Records
Varies
Price depends on data completeness, longitudinal tracking depth, demographic diversity, and clinical validation status of screening instruments used.
Longitudinal Patient Cohorts
Varies
Multi-visit screening score datasets with treatment outcomes command premium rates due to higher research and model training value for relapse prediction and treatment efficacy studies.
De-identified Clinical Trial Data
Varies
Pharmaceutical and academic institution datasets with regulated de-identification protocols and verified participant consent are highly valued for rigorous AI model development.
What Buyers Expect
What makes it valuable.valuable.
Standardized Screening Instruments
Data must be collected using validated, widely-recognized assessment tools (PHQ-9, GAD-7, DASS-42) with clearly documented scoring methodologies and severity classifications.
Clinical Population Representation
Datasets should represent intended-use populations (e.g., acute major depressive disorder, primary or psychiatric care settings, North American and Western European demographics) with appropriate psychiatric comorbidities included.
Longitudinal & Outcome Data
Multi-timepoint screening scores paired with treatment information and clinical outcomes enable stronger model training for differential treatment selection and relapse prediction capabilities.
Regulatory Compliance & De-identification
Data must meet HIPAA and regulatory standards with verified de-identification protocols, documented participant consent, and traceability to institutional review board approvals where applicable.
Companies Active Here
Who's buying.buying.
AI-powered mental health platform partnering with employers to deliver screening-based assessment and therapy support; recently expanded marketplace access through partnerships.
Pharmaceutical companies providing de-identified clinical trial data through controlled data request platforms to support AI model development for treatment selection and drug efficacy prediction.
Research organizations collecting longitudinal screening score data from patients in primary care and psychiatric settings for algorithm development and validation studies.
FAQ
Common questions.questions.
What screening instruments are most valuable for data buyers?
PHQ-9 for depression, GAD-7 for anxiety, and DASS-42 (42-item Depression Anxiety Stress Scales) are widely used standardized instruments. Depression screening is particularly valued because it has the most established standardized measures, making it easier for AI tools to support structured assessment and progress tracking at scale.
Who is driving demand for depression and anxiety screening data?
The AI-powered mental health solutions market is dominated by depression segment demand (26.3% market share in 2026), driven by its prevalence, standardized assessment protocols, and co-existence with anxiety and other conditions. Employers, payers, providers, and digital health platforms are actively seeking this data to improve care continuity and outcomes reporting.
How fast is the depression & anxiety screening data market growing?
The broader AI mental health market is projected to grow from $2.42 billion in 2026 to $9.96 billion by 2031, representing 32.74% CAGR. Depression and anxiety segments dominate, with depression and anxiety management apps capturing 29.78% of chatbot-based mental health app market share in 2024.
What makes longitudinal screening data more valuable?
Multi-timepoint screening score datasets paired with treatment information and clinical outcomes enable stronger AI model training for treatment selection algorithms and relapse prediction. Pharmaceutical companies and research institutions specifically seek longitudinal datasets from controlled clinical settings for rigorous algorithm validation.
Sell yourdepression & anxiety screening scoresdata.
If your company generates depression & anxiety screening scores, AI companies are actively looking for it. We handle pricing, compliance, and buyer matching.
Request Valuation